

Book before 15 February 2019  
and SAVE £200/€280

# Nasal Drug Delivery

To book online go to: [management-forum.co.uk/936](http://management-forum.co.uk/936)

W

## Dates and venue

11-12 April 2019

Ref: 10381

HI London - Kensington Forum  
97 Cromwell Road  
London  
SW7 4DN  
Phone: +44 (0) 207 341 3355

## Programme schedule

Registration and refreshments: 09.00  
Day one: 9.30 – 17.30  
Drinks reception: 17.30 – 18.30  
Day two: 9.15 – 16.15

## Accommodation

We have arranged a preferential rate for accommodation at the venue. To take advantage of this, please contact the hotel and state you are a Management Forum delegate quoting the special code 'QGM'. There are limited rooms available at this rate, so please book early to avoid disappointment.

Email: [reservations@hikensington.co.uk](mailto:reservations@hikensington.co.uk)  
Web: [www.hikensingtonforumhotel.co.uk](http://www.hikensingtonforumhotel.co.uk)

For information on alternative accommodation, please visit our website: [management-forum.co.uk/accommodation](http://management-forum.co.uk/accommodation)



## Three ways to book

[management-forum.co.uk](http://management-forum.co.uk) [info@management-forum.co.uk](mailto:info@management-forum.co.uk) +44 (0)20 7749 4730

## Fees and payment

### EARLY BOOKING DISCOUNT Book BEFORE 15 February 2019

£1299.00 + VAT = £1558.80 • €1819.00 + VAT = €2182.80

### FULL PRICE Book AFTER 15 February 2019

£1499.00 + VAT = £1798.80 • €2099.00 + VAT = €2518.80

### Multiple booking discount for 2nd or subsequent delegates - 15%

£1274.15 + VAT = £1528.98 • €1784.15 + VAT = €2140.98

### Payment options

1. Invoice which can be paid by bank transfer or credit/debit card
2. Online through our secure website when registering

### Exhibition opportunities available

Please contact Customer Services on +44 (0)20 7749 4730 or email: [info@management-forum.co.uk](mailto:info@management-forum.co.uk)



## Management Forum in-house training

Coming to Management Forum for your in-house training provides an all-inclusive service which gives you access to a wide variety of content, learning platforms and delivery mechanisms as well as your own personal training adviser who will work with you from the initial enquiry through to feedback and follow-up after the programme.

With over 600 trainers, practitioners and experts across a huge range of fields, we can provide the training you need, where you need it, when you need it, and at a price which suits your budget. Our approach to tailored learning and development consists of designing and delivering the appropriate solution for each client.

To get a **FREE** consultation and to find out how we can work with you call **Aleksandra**, our in-house training expert, on +44 (0) 20 7749 4730 or email [inhouse@management-forum.co.uk](mailto:inhouse@management-forum.co.uk)

To find out more, please visit: [management-forum.co.uk](http://management-forum.co.uk)



FEE: The fee includes all meals and refreshments for the duration of the course and a complete set of course materials. If you have any particular requirements, please advise customer services when booking.

PLEASE NOTE: Management Forum Ltd reserve the right to change the content and timing of the programme, the speakers, the date and venue due to reasons beyond their control. In the unlikely event that the course is cancelled, Management Forum will refund the registration fee and disclaim any further liability.



For event cancellation policy and T&Cs see our website

7653

Book Before  
15 February 2019  
and SAVE £200/€280

Media Partner




# Nasal Drug Delivery

An essential update on the latest scientific developments, technology advances and regulatory guidance

11-12 April 2019 London

## Programme to include:

- Nasal drugs to treat nasal disorders: a comprehensive review
- Review of nasal drug delivery devices
- Nasal formulation of drugs
- Rethinking nasal packaging environment
- The unique challenges of nasal drug delivery to treat chronic rhinosinusitis (CRS); considerations before and after sinus surgery
- Key insights for a successful device development to achieve nasal bioequivalence requirements
- Requirements concerning bioequivalence of nasal drug products from an authority's point of view
- Regulatory science associated with BE/TE for nasal products
- Qualification of new nasal drug delivery systems for existing drugs
- Investigations regarding the developability of nasal metered dose inhalers



### Co-chaired by:

**Dr Julie Suman**, President, Next Breath, USA

**Dr René Bommer**, Director, pharmAccel Consulting, Germany

### Keynote speaker:

**Professor Valerie Lund**, Professor Emeritus of Rhinology at the Ear Institute, University College London

## With a panel of expert speakers

Exhibition opportunities available



**Why you should attend this seminar**

What makes nasal delivery systems more challenging than solid dosage forms? How safe is nasal drug delivery? Are there such things as safe excipients? How does all this fit within the regulatory environment in Europe and the USA? How difficult is it to bring all these products to market?

This seminar seeks to explore these and other questions within the field of nasal drug delivery while reviewing interesting new data, innovative technologies and the very latest scientific developments. Leading authorities in nasal drug delivery will cover relevant aspects of nasal physiology, anatomy, absorption of a variety of drugs in various phases of drug development, and new drugs entering the market. In addition, nasal delivery to the sinuses will be discussed and the programme will include interesting case histories.

This seminar will offer an excellent networking opportunity to build business relationships and discuss all these issues with an unrivalled panel of experts in this field of drug delivery.

**Who should attend?**

- Managing directors
- Medical directors
- Heads of regulatory affairs
- Quality assurance managers
- Senior executives in research and development
- Registration associates
- Marketing managers
- All departments that are involved in nasal drug delivery, or who wish to understand the potential of this alternative therapeutic route

Those already involved in nasal drug delivery will benefit from updating their knowledge and sharing experiences with some of the leading practitioners in this field. If you are involved in nasal drug delivery or are just considering the potential, this seminar is an excellent route to understanding all aspects from the basic physiology through to launching a successful product

**Co-chairs**

**Dr Julie Suman**, President, Next Breath, USA  
**Dr René Bommer**, Director, pharmAccel Consulting, Germany

**Expert faculty**

**Professor Valerie Lund**, Professor Emeritus of Rhinology at the Ear Institute, University College London  
**Dr Regina Scherliess**, Christian Albrecht University of Kiel, Department of Pharmaceutics and Biopharmaceutics, Germany  
**Christopher Fuller**, Associate Director, Engineering, Impel NeuroPharma  
**Lee Lucas**, Vice President of Applications and Business Development, Aptar CSP Technologies, USA  
**Pascale Farjas**, Global Category Manager, Nemera, France  
**Céline Petitcolas**, Customer Technical Support, Nemera, France  
**Per Djupesland**, CSO, Optinose, Norway  
**Dr Cornelia Nopitsch-Mai**, German Regulatory Authority, BfArM  
**Anders Fuglsang**, Industry Consultant, Fuglsang Pharma, Denmark  
**Andrew Wood**, Associate Director Regulatory Affairs, Aptar Pharma, France  
**Thomas Grinnan**, Senior Commercial Director, Healthcare, Silgan Dispensing Systems, France  
**Dr Jag Shur**, Director, Nanopharm, UK  
**Dr John Warren**, Director, Medicines Assessment, UK

Day one	
09.00	▶ <b>Registration and refreshments</b>
09.30	▶ <b>Welcome and introduction</b> <i>Dr Julie Suman and Dr René Bommer</i>
09.45	▶ <b>Nasal drugs to treat nasal disorders: a comprehensive review</b> <ul style="list-style-type: none"> <li>• Anatomy and physiology</li> <li>• Nasal disorders</li> <li>• Treatment options and future prospects to treat allergic and non-allergic rhinitis</li> <li>• CRS with and without nasal polyps</li> </ul> <b>Professor Valerie Lund</b>
10.45	▶ <b>Discussion session</b>
11.00	▶ <b>Refreshments</b>
11.30	▶ <b>Nasal drug delivery challenges</b> <ul style="list-style-type: none"> <li>• Discuss ideal attributes of a nasal spray formulation</li> <li>• Present strategies to optimise deposition</li> <li>• Highlight excipients to facilitate absorption</li> <li>• Present technology for delivery and formulation characterisation</li> </ul> <b>Dr Julie Suman</b>
12.10	▶ <b>Nasal formulation of drugs</b> <ul style="list-style-type: none"> <li>• Formulation aspects of liquid systems</li> <li>• Carrier-based and matrix dry powder formulations for nasal delivery</li> <li>• (Nano)particulate drug carriers for nasal administration</li> <li>• Interplay of therapeutic targets and nasal deposition</li> </ul> <b>Dr Regina Scherliess</b>
12.50	▶ <b>Discussion session</b>
13.00	▶ <b>Lunch</b>
14.00	▶ <b>Developing next generation powder nasal delivery using POD technology</b> <ul style="list-style-type: none"> <li>• Device development efforts</li> <li>• Formulation development efforts</li> <li>• Unique challenges to powder delivery</li> </ul> <b>Christopher Fuller</b>
14.40	▶ <b>Rethinking nasal packaging environment</b> <ul style="list-style-type: none"> <li>• Using integrated three-phase activ-polymer to control moisture ingress</li> <li>• Extend shelf life</li> <li>• Improve performance</li> </ul> <b>Lee Lucas</b>
15.20	▶ <b>Discussion session</b>
15.30	▶ <b>Refreshments</b>
16.00	▶ <b>Key insights for a successful device development to achieve nasal bioequivalence requirements</b> <ul style="list-style-type: none"> <li>• Design and testing techniques for nasal spray devices</li> <li>• In-Vitro BioEquivalence (IVBE) requirements and region-specific regulatory strategies</li> <li>• Statistical tools and new alternative approach applied to nasal sprays</li> <li>• Key success factors for nasal spray development projects</li> </ul> <b>Pascale Farjas and Céline Petitcolas</b>
16.40	▶ <b>The unique challenges of nasal drug delivery to treat chronic rhinosinusitis (CRS); considerations before and after sinus surgery</b> <ul style="list-style-type: none"> <li>• Medical therapy in CRS – goals and challenges</li> <li>• Endoscopic sinus surgery – implications for drug deposition</li> <li>• Nasal delivery methods – advantages and limitations</li> </ul> <b>Per Djupesland</b>
17.20	▶ <b>Discussion session</b>
17.30	▶ <b>End of day one</b>
17.30-18.30	<b>Drinks reception for delegates and speakers</b>

Day two	
09.15	▶ <b>Review of day one</b> <i>Dr Julie Suman and Dr René Bommer</i>
09.30	▶ <b>Review of nasal drug delivery devices</b> <ul style="list-style-type: none"> <li>• Trends in nasal delivery systems</li> <li>• Advances in device technologies</li> <li>• Nasal spray characteristics</li> </ul> <b>Dr René Bommer</b>
10.10	▶ <b>Requirements concerning bioequivalence of nasal drug products from an authority's point of view</b> <ul style="list-style-type: none"> <li>• Bioequivalence of nasal products</li> <li>• The evaluation of the monograph for nasal products in the European Pharmacopoeia will be outlined</li> </ul> <b>Dr Cornelia Nopitsch-Mai</b>
10.50	▶ <b>Discussion session</b>
11.00	▶ <b>Refreshments</b>
11.30	▶ <b>Regulatory science associated with BE/TE for nasal products</b> <ul style="list-style-type: none"> <li>• Average BE versus population BE</li> <li>• End point right, outcome wrong: why?</li> <li>• Getting the sample size right</li> <li>• Lessons learned from inhaled aerosol products</li> </ul> <b>Anders Fuglsang</b>
12.10	▶ <b>US/FDA regulatory guidance on combination products</b> <ul style="list-style-type: none"> <li>• Origin and objective of the regulations</li> <li>• The regulation and guidance documents</li> <li>• Requirements and expectations of FDA</li> </ul> <b>Andrew Wood</b>
12.50	▶ <b>Discussion session</b>
13.00	▶ <b>Lunch</b>
14.00	▶ <b>Qualification of new nasal drug delivery systems for existing drugs</b> <ul style="list-style-type: none"> <li>• Formulation analysis</li> <li>• System and compatibility</li> <li>• Stability testing</li> <li>• Performance testing</li> <li>• Production line and efficiency optimisation</li> </ul> <b>Thomas Grinnan</b>
14.40	▶ <b>Investigations regarding the developability of nasal metered dose inhalers</b> <ul style="list-style-type: none"> <li>• Findings</li> <li>• Opportunities</li> </ul> <b>Dr Jag Shur</b>
15.20	▶ <b>What are chemisimilars and what's the problem?</b> <ul style="list-style-type: none"> <li>• Standardisation</li> <li>• EU guidance</li> <li>• FDA guidance</li> <li>• Assay sensitivity and the best models to test for similarity</li> </ul> <b>Dr John Warren</b>
16.00	▶ <b>Discussion session</b>
16.10	▶ <b>Concluding remarks</b>
16.15	▶ <b>Close of conference and refreshments</b>